Volume 4, Issue 2, March 2018, Page: 26-31
Nonalcoholic Fatty Liver Disease and the Risk of Incident Chronic Kidney Disease: A Meta-Analysis
Yichao Zheng, Department of Gastroenterology, Zhangzhou Municipal Hospital of Fujian Medical University, Zhangzhou, China
Yifen Wu, Department of Hemodialysis, Zhangzhou Municipal Hospital of Fujian Medical University, Zhangzhou, China
Yadong Lai, Department of Gastroenterology, Zhangzhou Municipal Hospital of Fujian Medical University, Zhangzhou, China
Hanxu Zhuang, Department of Gastroenterology, Zhangzhou Municipal Hospital of Fujian Medical University, Zhangzhou, China
Guian Zheng, Department of Internal Medicine, Zhangzhou Municipal Hospital of Fujian Medical University, Zhangzhou, China
Received: Apr. 14, 2018;       Accepted: May 2, 2018;       Published: May 19, 2018
DOI: 10.11648/j.ijcems.20180402.12      View  1117      Downloads  60
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease that affects many extrahepatic-organ systems. In this respect, several studies have suggested the possible association between NAFLD and the risk of incident chronic kidney disease (CKD). However, the extent of this association remains unclear. Thus the present meta-analysis was conducted to better characterize this association. In the meta-analysis, a comprehensive search of the databases of MEDLINE, EMBASE, Web of Science and Cochran Library was carried out from inception through September 2017. All large observational studies that investigated the association between NAFLD and the risk of incident CKD were included. The incident CKD was defined as occurrence of estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2 and/or overt proteinuria. The pooled hazard ratio (HR) with 95% confidence intervals (CIs) was calculated using the random-effects model. Data were extracted from 5 large observational studies involving 57,341 adult individuals (41.3% with NAFLD) with 1,886 cases of incident CKD. NAFLD is significantly associated with increased risk of incident CKD (HR 1.40, 95%CI 1.22-1.61). The statistical heterogeneity of included studies was low, with an I2=25.4%. In conclusion, the present meta-analysis confirms the association between NAFLD and the risk of incident CKD.
Keywords
Nonalcoholic Fatty Liver, Chronic Kidney Disease, Meta-Analysis
To cite this article
Yichao Zheng, Yifen Wu, Yadong Lai, Hanxu Zhuang, Guian Zheng, Nonalcoholic Fatty Liver Disease and the Risk of Incident Chronic Kidney Disease: A Meta-Analysis, International Journal of Clinical and Experimental Medical Sciences. Vol. 4, No. 2, 2018, pp. 26-31. doi: 10.11648/j.ijcems.20180402.12
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285.
[2]
Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9:524.e1–530.e1.
[3]
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62 (Suppl):S47–S64.
[4]
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66:1138-1153.
[5]
Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 2014; 64:638-652.
[6]
Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol 2017; 13:297-310.
[7]
Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol Sci 2017; 38:649-665.
[8]
Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 2017; 13:509-520.
[9]
Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol 2016; 65:425-443.
[10]
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 2000; 283:2008–2012.
[11]
Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25:603–605.
[12]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557–560.
[13]
Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008; 57:569-576.
[14]
Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19:1564-1570.
[15]
Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011; 50:1081-1087.
[16]
Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014; 37:1729-1736.
[17]
Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, et al. Nonalcoholic fatty liver disease and development of chronic kidney disease: a retrospective cohort study. J Hepatol 2017; 66 (Suppl): S155.
[18]
Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One 2017; 12:e0180951.
[19]
Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001680.
[20]
Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C, et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 2005; 49:289-295.
[21]
Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29:113-119.
[22]
Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45:1929-34.
[23]
Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5:1544-60.
[24]
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64:1388-1402.
[25]
Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20:7392–7402.
[26]
Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 2014; 29:1149-58.
Browse journals by subject